Other formats:
BibTeX
LaTeX
RIS
@article{2211017,
author = {Baliakas, Panagiotis and Espinet, Blanca and Mellink, Clemens and Jarošová, Marie and Athanasiadou, Anastasia and Ghia, Paolo and Kater, Arnon P and Oscier, David and Haferlach, Claudia and Stamatopoulos, Kostas},
article_location = {Philadelphia},
article_number = {4},
doi = {http://dx.doi.org/10.1097/HS9.0000000000000707},
keywords = {Chronic Lymphocytic Leukemia; Cytogenetics},
language = {eng},
issn = {2572-9241},
journal = {HemaSphere},
title = {Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations},
url = {https://journals.lww.com/hemasphere/Fulltext/2022/04000/Cytogenetics_in_Chronic_Lymphocytic_Leukemia__ERIC.6.aspx},
volume = {6},
year = {2022}
}
TY - JOUR
ID - 2211017
AU - Baliakas, Panagiotis - Espinet, Blanca - Mellink, Clemens - Jarošová, Marie - Athanasiadou, Anastasia - Ghia, Paolo - Kater, Arnon P - Oscier, David - Haferlach, Claudia - Stamatopoulos, Kostas
PY - 2022
TI - Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations
JF - HemaSphere
VL - 6
IS - 4
SP - 1-7
EP - 1-7
PB - Lippincott Williams & Wilkins
SN - 25729241
KW - Chronic Lymphocytic Leukemia
KW - Cytogenetics
UR - https://journals.lww.com/hemasphere/Fulltext/2022/04000/Cytogenetics_in_Chronic_Lymphocytic_Leukemia__ERIC.6.aspx
N2 - Mounting evidence underscores the clinical value of cytogenetic analysis in chronic lymphocytic leukemia (CLL), particularly as it allows the identification of complex karyotype, that has recently emerged as a prognostic and potentially predictive biomarker. That said, explicit recommendations regarding the methodology and clinical interpretation of either chromosome banding analysis (CBA) or chromosome microarray analysis (CMA) are still lacking. We herein present the consensus of the Cytogenetic Steering Scientific Committee of ERIC, the European Research Initiative on CLL, regarding methodological issues as well as clinical interpretation of CBA/CMA and discuss their relevance in CLL. ERIC considers CBA standardized and feasible for CLL on the condition that standards are met, extending from the use of novel mitogens to the accurate interpretation of the findings. On the other hand, CMA, is also standardized, however, robust data on its clinical utility are still scarce. In conclusion, cytogenetic analysis is not yet mature enough to guide treatment choices in CLL. That notwithstanding, ERIC encourages the wide application of CBA, and potentially also CMA, in clinical trials in order to obtain robust evidence regarding the predictive value of specific cytogenetic profiles towards refining risk stratification and improving the management of patients with CLL.
ER -
BALIAKAS, Panagiotis, Blanca ESPINET, Clemens MELLINK, Marie JAROŠOVÁ, Anastasia ATHANASIADOU, Paolo GHIA, Arnon P KATER, David OSCIER, Claudia HAFERLACH and Kostas STAMATOPOULOS. Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations. \textit{HemaSphere}. Philadelphia: Lippincott Williams \&{} Wilkins, 2022, vol.~6, No~4, p.~1-7. ISSN~2572-9241. Available from: https://dx.doi.org/10.1097/HS9.0000000000000707.
|
